Palvella Therapeutics gains FDA priority review with February decision target

A potential first FDA-approved treatment for microcystic lymphatic malformations has a Feb. 28, 2027 FDA target action date after Palvella Therapeutics, Inc. NASDAQPVLA received application acceptance and priority review, the company said Wednesday. Palvella is preparing for a standalone U.S. launch in the first half of 2027, subject to approval.

The Oct. 28 announcement covers a new drug application for QTORIN 3.9 per cent rapamycin anhydrous gel. Palvella estimates more than 30,000 people in the United States have diagnosed microcystic lymphatic malformations, which can cause persistent leaking, bleeding and recurrent infections.

Palvella is a small clinical-stage biotechnology company based in Wayne, Pa., developing treatments for rare skin diseases and vascular anomalies.

Shares NASDAQPVLA closed at US$132.91 on Nasdaq at 4:00 p.m. EDT on Oct. 27, before Wednesday's announcement. The next regulatory milestone is an FDA action on the application, rather than permission to begin selling the gel.

"FDA acceptance of our NDA and granting of Priority Review represent significant milestones in the development of QTORIN™ rapamycin as a potential first FDA-approved therapy for microcystic lymphatic malformations," founder and chief executive Wes Kaupinen said in the release.

Priority review accelerates the review goal without reducing the approval standard. The FDA's explanation sets a six-month action goal against ten months for standard review and says the designation does not change the evidence required.

The application also includes Phase 2 results and published literature on off-label rapamycin use in the condition.

The supporting Phase 3 SELVA trial was single-arm and baseline-controlled, so its results measure improvement against patients' starting condition rather than a concurrent placebo group. Palvella's Feb. 24 results reported that 51 participants enrolled and 50 began treatment.

The efficacy population comprised 49 participants aged six or older. At week 24, the primary investigator assessment improved by a mean 2.13 points, with a p value below 0.001; the scale ranges from very much worse to very much improved.

Among the 43 participants in that age group who completed the efficacy evaluation, 41 improved. That is the basis of the company's 95 per cent headline, rather than a response rate across everyone enrolled.

All six prespecified efficacy endpoints had p values below 0.001. Four treated participants experienced serious adverse events, all judged unrelated to the drug by investigators, while treatment-related events were mild or moderate.

Commercial Preparation Precedes The FDA Decision

Palvella's Aug. 4 update said its pre-application FDA meeting addressed clinical information and the proposed evidence package, after which the agency granted rolling review. It also reported US$250.6 million in cash, equivalents and short-term investments at June 30.

Read more: Zura Bio keeps 2028 cash runway ahead of year-end tibulizumab data

Wednesday's release describes commercial leadership, a field medical team and patient services already in place. Remaining preparations include patient identification, market access planning and support readiness; the launch remains conditional on approval.

A commercial comparison in rare skin disease is Krystal Biotech, Inc. NASDAQKRYS. Its Aug. 3 results reported US$119.2 million in second-quarter global VYJUVEK revenue for dystrophic epidermolysis bullosa, alongside ongoing pricing and reimbursement discussions in European markets.

For broader sector context, the iShares Biotechnology ETF NASDAQIBB closed at US$208.69 at 4:00 p.m. EDT on Oct. 26. That dated benchmark also precedes Palvella's announcement.

The next fixed date is Feb. 28, 2027, when the FDA targets action on QTORIN rapamycin's application. Approval would allow Palvella to pursue its planned first-half launch; acceptance and priority review alone do not authorize it.